NO

NovMetaPharma Co., Ltd.

Develops first-in-class drugs for metabolic and fibrotic diseases.

229500 | KO

Overview

Corporate Details

ISIN(s):
KR7229500004
LEI:
Country:
South Korea
Address:
서울특별시 강남구 언주로 727 13층 (논현동, 트리스빌딩), 강남구

Description

NovMetaPharma Co., Ltd. is a biopharmaceutical company specializing in the research and development of first-in-class drugs with differentiated mechanisms. The company focuses on creating novel therapeutics for metabolic and fibrotic diseases, addressing significant unmet medical needs. Its main pipeline includes drug candidates for type 2 diabetes (NovDB2), obesity (NovOB), chronic kidney disease (NovRD), and fibrosis (NovFS). The company's lead assets in clinical development are Cyclo-Z and CHP. NovMetaPharma aims to develop innovative treatments by leveraging its core research teams and efficient development systems to target the root causes of these complex conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-05-15 00:00
기업설명회(IR)개최결과
Korean 6.6 KB
2025-05-13 00:00
특허권취득(자율공시)
Korean 4.8 KB
2025-04-29 00:00
기업설명회(IR)개최
Korean 7.0 KB
2025-03-31 00:00
주식등의대량보유상황보고서(일반)
Korean 170.5 KB
2025-03-25 00:00
증권발행결과(자율공시)
Korean 5.3 KB
2025-03-24 00:00
정기주주총회결과
Korean 20.3 KB
2025-03-24 00:00
주식매수선택권부여에관한신고
Korean 22.1 KB
2025-03-14 00:00
사업보고서 (2024.12)
Korean 361.6 KB
2025-03-13 00:00
감사보고서제출
Korean 9.4 KB
2025-03-07 00:00
주주총회소집결의
Korean 11.0 KB
2025-03-07 00:00
주주총회소집공고
Korean 238.9 KB
2025-03-06 00:00
주요사항보고서(유상증자결정)
Korean 66.1 KB
2025-02-05 00:00
특허권취득(자율공시)
Korean 5.6 KB
2024-12-20 00:00
기업설명회(IR)개최결과
Korean 6.7 KB
2024-12-17 00:00
특허권취득(자율공시)
Korean 6.1 KB

Automate Your Workflow. Get a real-time feed of all NovMetaPharma Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NovMetaPharma Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NovMetaPharma Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.